Chronic Heart Failure
Conditions
Brief summary
Change in echocardiographic measurements from Baseline to Week 25
Detailed description
Change in echocardiographic measurements from Baseline to Week 13 and Week 25, • Change in Health Status from Baseline to Week 3, Week 5, Week 13, and Week 25 • Change in NYHA FC from Baseline to Week 25, Change echocardiographic measurements from baseline to week 25, Change in cardiac biomarkers from Baseline to Week 5, Week 13, and Week 25, AZD5462 plasma PK concentrations
Interventions
DRUGAZD5462
DRUGThe AZD5462 film-coated tablet placebo contains microcrystalline cellulose
DRUGmagnesium stearate
DRUGtitanium dioxide
DRUGmacrogol (polyethylene glycol) and talc. It is supplied in the same pack as the active and should be stored according to instructions on the label.
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in echocardiographic measurements from Baseline to Week 25 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in echocardiographic measurements from Baseline to Week 13 and Week 25, • Change in Health Status from Baseline to Week 3, Week 5, Week 13, and Week 25 • Change in NYHA FC from Baseline to Week 25, Change echocardiographic measurements from baseline to week 25, Change in cardiac biomarkers from Baseline to Week 5, Week 13, and Week 25, AZD5462 plasma PK concentrations | — |
Countries
Bulgaria, Czechia, Denmark, Hungary, Netherlands, Poland, Slovakia
Outcome results
None listed